Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
$25.44
$1.23M1.4122,322 shsN/A
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
$0.98
+0.8%
$0.95
$0.80
$2.18
$4.19M0.93609,657 shs42,852 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.64
+1.8%
$0.69
$0.25
$4.71
$9.04M1.382.54 million shs2.43 million shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.62
-1.6%
$3.19
$1.75
$9.00
$5.95M1.33799,435 shs55,613 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%-56.52%
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
-1.70%-6.23%+13.15%+0.21%-56.22%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-0.22%+20.58%-2.07%-31.59%-85.10%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00%+18.33%+19.09%+55.93%+844.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.9157 of 5 stars
0.04.00.00.02.71.70.0
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2.9838 of 5 stars
3.52.00.00.03.21.71.3
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.7242 of 5 stars
0.05.00.00.02.80.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00
N/AN/AN/A
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.00
N/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.00
Buy$4.00525.00% Upside
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ASLN, SNOA, MBRX, and CMND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/9/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$4.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$12M0.10N/AN/A($6.50) per share-0.09
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/A$0.73 per shareN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$1.77 per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.29M0.42N/AN/A$2.73 per share1.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
-$44.22M-$21.92N/AN/AN/A-8,454.87%-121.60%N/A
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
-$5.26M-$1.10N/AN/AN/A-164.79%-71.12%N/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$3.10N/AN/AN/A-24.23%-58.73%-21.05%8/6/2025 (Estimated)

Latest ASLN, SNOA, MBRX, and CMND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$0.42N/AN/AN/AN/AN/A
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
6/12/2025Q2 2025
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A-$0.16N/A-$0.16N/AN/A
5/13/2025Q1 2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$0.71-$0.69+$0.02-$0.69N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/A
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/A
1.05
1.05
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A
1.74
1.74
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
1.35
1.35
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.09
2.38

Institutional Ownership

CompanyInstitutional Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
58.82%
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
96.05%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
302.04 million1.95 millionOptionable
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A4.27 millionN/ANot Optionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2014.13 million13.83 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.58 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market
Sonoma Pharmaceuticals, Inc. (O8Z.F)

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLAN Pharmaceuticals stock logo

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)
As of 07/15/2025

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Clearmind Medicine stock logo

Clearmind Medicine NASDAQ:CMND

$0.98 +0.01 (+0.82%)
Closing price 04:00 PM Eastern
Extended Trading
$0.95 -0.03 (-2.65%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.64 +0.01 (+1.80%)
Closing price 04:00 PM Eastern
Extended Trading
$0.64 0.00 (-0.47%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.62 -0.06 (-1.63%)
Closing price 04:00 PM Eastern
Extended Trading
$3.60 -0.02 (-0.55%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.